Form D · Pharmaceuticals
SteadyMed Ltd.
Rehovot, L3 · CIK 0001619087
Offering snapshot reported May 8, 2017 · SEC filing
- Reported sold
- $30M Offering amount: $30M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 25, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2017 | Initial | $30,000,617 | No comparison | 19 | SEC filing |
| Aug 17, 2016 | Initial | $21,333,322 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.73M (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-286176
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| JMP Securities LLC | 22208 | |
| H.C. Wainwright & Co. | 375 |
Source: Form D, filed May 8, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Keith Bank | Director |
| Elizabeth Cermak | Director |
| Stephen Farr | Director |
| Ron Ginor | Director |
| Donald Huffman | Director |
| David W. Nassif | Executive |
| Jonathan Rigby | Director, Executive |
| Brian Stark | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5 Oppenheimer Street
Rehovot, L3, 76701
Rehovot, L3, 76701